Metabolite Biomarker Panels for Non-Invasive CRC/ACRA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting colorectal cancer (CRC) and advanced colorectal adenoma (ACRA) are either invasive, causing discomfort, or non-invasive methods lack accuracy and reliability, necessitating the development of non-invasive biomarkers for early detection.
Innovation Solution
A system utilizing a set of target metabolites, quantified by mass spectrometry, processed through a prediction model to determine a sample score, and compared to a cut-off score for CRC/ACRA detection, enabling non-invasive diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive diagnostic methods (colonoscopy, biopsy) are used, then diagnostic accuracy is improved, but patient comfort deteriorates due to discomfort, pain, or tissue damage
Solution Approach 1:
The patent uses metabolites in body fluids (urine, blood, saliva) as intermediary markers that reflect the presence of CRC or ACRA without requiring direct contact with or manipulation of the colorectal tissue. These metabolite profiles serve as mediators between the disease state and the diagnostic measurement, enabling non-invasive detection while maintaining diagnostic accuracy
Solution Approach 2:
The patent replaces the mechanical invasive approach of colonoscopy and biopsy with a biochemical measurement system. Instead of physically examining or sampling colorectal tissue, the system measures metabolite concentrations in body fluids using analytical instruments, substituting mechanical intrusion with chemical analysis
2Object-affected harmful factors
If non-invasive diagnostic methods (FOBT, CEA) are used, then patient comfort is improved, but diagnostic accuracy deteriorates
Solution Approach 1:
The patent segments the complex metabolic profile into multiple individual metabolite measurements rather than relying on a single biomarker. By analyzing a panel of metabolites (including but not limited to hippuric acid, phenylacetic acid, indoleacetic acid, and their derivatives) and combining their information, the system achieves higher diagnostic accuracy than single-marker non-invasive tests
Solution Approach 2:
The patent creates a composite diagnostic approach by combining multiple metabolite measurements into an integrated assessment. The diagnostic result is derived from the collective information of various metabolite profiles rather than any single metabolite, similar to how composite materials combine multiple components to achieve superior properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively distinguishes between normal and CRC/ACRA subjects, facilitating early detection and potential treatment, improving survival rates through non-invasive means.
Implementation Method 1
obtaining, from a quantitative measurement device, quantified abundance of one or more target metabolites in a panel of a plurality of metabolites
Data Source
AI summary
A group of diagnostic biomarkers usable for diagnosis of colorectal cancer or advanced colorectal adenoma (CRC/ACRA) is provided. The method for detecting CRC/ACRA using the group of diagnostic biomarkers is also provided. For example, the method is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage). A kit for detecting CRC/ACRA is also provided.